XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 2 - Significant Accounting Policies (Details Textual)
 3 Months Ended 6 Months Ended
Apr. 22, 2024
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Sep. 22, 2023
shares
Amortization of above and below Market Leases   $ 1,244   $ 2,487          
Deferred Costs   1,600,000       $ 1,600,000   $ 1,700,000  
Operating Lease, Initial Direct Cost Expense, over Term   119,278   122,330   244,099 $ 228,151    
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents   8,534,881       8,534,881   6,510,428  
Restricted Cash   3,200,000       3,200,000   3,700,000  
Cash, Uninsured Amount   3,200,000       3,200,000   700,000  
Unamortized Deferred Stock Costs   0       0   5,000  
Impairment of Real Estate   101,245   0   196,793 $ 0    
Proceeds from Sale of Real Estate           20,100,000      
Gain (Loss) on Sale of Properties           2,800,000      
Marketable Securities   0       0   45,149  
Marketable Securities, Cost Basis               40,315  
Equity Securities, FV-NI   4,413,989       4,413,989   18,318,521  
Accounts Payable and Accrued Liabilities   3,501,779       3,501,779   4,770,845  
Revision of Prior Period, Error Correction, Adjustment [Member]                  
Accounts Payable and Accrued Liabilities               (21,189)  
Additional Paid in Capital               21,189  
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition     $ 317,077 $ 228,657 $ 232,106        
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 540,000               754,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 3.12                
Warrants and Rights Outstanding, Term (Year) 2 years                
Warrant or Right, Exercisable Period (Year) 1 year                
Warrants and Rights Outstanding $ 891,000 156,600       156,600      
Conduit Pharmaceuticals Inc [Member]                  
Lock-up Agreement, Shares (in shares) | shares 2,700,000                
Investment Owned, Balance, Shares (in shares) | shares 4,015,250                
Equity Securities, FV-NI   4,300,000       4,300,000   18,300,000  
Investment Owned, Fair Value   $ 4,400,000       $ 4,400,000      
Fair Value, Inputs, Level 1 [Member]                  
Marketable Securities               $ 45,149  
Discontinued Operations, Disposed of by Sale [Member]                  
Number of Real Estate Properties   42   10   42 10    
Proceeds from Sale of Real Estate           $ 20,100,000 $ 4,600,000    
Gain (Loss) on Sale of Properties           2,800,000 1,500,000    
Finite-lived Intangibles, Other Than Lease Intangibles [Member]                  
Amortization of Intangible Assets   $ 4,382   $ 8,763   $ 4,382 $ 8,763    
Minimum [Member]                  
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   1 year       1 year      
Leasehold Improvements [Member] | Maximum [Member]                  
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   10 years       10 years      
Furniture and Fixtures [Member] | Maximum [Member]                  
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   5 years       5 years      
Furniture and Fixtures [Member] | Minimum [Member]                  
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year)   1 year       1 year      
Murphy Canyon Acquisition Sponsor, LLC (SPAC) [Member]                  
Subsidiary, Ownership Percentage, Parent                 65.00%